

Original Research Article

<https://doi.org/10.20546/ijcmas.2018.708.xx>

Identification and Antifungal Susceptibility of *Candida* Isolates from Clinical Samples in a Tertiary Care Teaching Hospital of Central Uttar Pradesh

Seema Bose, Amita Arya and Anjali Agarwal

Department of Microbiology, Hind Institute of Medical Sciences, Safedabad,
Uttar Pradesh, India

*Corresponding author

ABSTRACT

Keywords

Candida albicans,
Non – *albicans*
Candida, Antifungal
susceptibility,
Ketoconazole

Article Info

Accepted:
xx July 2018
Available Online:
xx August 2018

Candida albicans (*C.albicans*) is considered as the commonest cause of Candidiasis. But recently incidence of non – *albicans* *Candida*(NAC) infection has increased. The most commonly used drugs against candidiasis are azole derivatives. Resistance pattern of different *Candida* species (*spp*) varies widely, some of them being inherently resistant. This study was undertaken to find out incidence of Candidiasis, their species identification and susceptibility of azole derivatives. In 6 months period, total 43 *Candida spp.* were isolated from various clinical samples, among which *C. albicans* (46.5%), *C.tropicalis* (24.5%), *C. glabrata* (23.4%) and *C.krusie* (4.6%). Susceptibility to Ketoconazole (KT), Fluconazole (FLC) and Itraconazole (IT) were detected.

Introduction

Modernization of medical science has caused dramatic changes in patient care. Side by side, it also has introduced emergence and re-emergence of certain microorganisms. Due to increasing use of life-saving medical devices, incidence of device-associated infection is rising steadily. Previously, fungal infection was usually restricted to cutaneous and mucocutaneous surfaces. Now it has emerged as life-threatening pathogenic organism all over the world. Candidiasis is also a major cause of morbidity and mortality in terminally

ill patients (Snydman D. R. 2003, Sardi J. C. *et al.*, 2013). Though *Candida albicans* is considered as most pathogenic species of genus *Candida*, now a day, there is a shift towards non-*albicans* *Candida* species (Sullivan *et al.*, 1996).

The present study was undertaken in the microbiology department of a tertiary care medical college and hospital. The institute is situated in a rural set up of central Uttar Pradesh, catering mainly rural population of lower socio-economic class.

Aims and objective

This study was undertaken to identify *Candida* isolates from various clinical samples up to species level and to find out their antifungal susceptibility.

Material and Methods

This was a prospective, cross – sectional study. The study period is 6 months. Clinical samples like blood, urine, pus, sputum, catheter tips, vaginal swabs and throat swabs were processed in the microbiology department. In this study, all *Candida* isolates from culture of various clinical specimens were further tested for species identification and antifungal susceptibility.

Inclusion criteria – *Candida* isolates from all clinical specimen in pure culture.

Exclusion criteria – Repeat isolates from same clinical specimen of same patient and isolation of *Candida* species from mix culture.

Candida spp. is a commensal of vagina and buccal cavity. Therefore, demonstration on gram staining of smear and isolation in culture were done to diagnose cases of oropharyngeal and vulvovaginal candidiasis. In urine sample, colony counts of $>10^5$ cfu/ml was considered as significant candiduria in patients without indwelling catheters. In catheterized patients, 1000 cfu/ml indicated significant candiduria. Isolation of very less no of *Candida* spp was considered significant from sterile body fluids like blood, cerebrospinal fluid, pleural fluid and peritoneal fluid (Kauffman CA.2005).

All culture isolates were identified up to species level following standard mycological protocol, such as; germ tube production, chlamydospore formation, carbohydrate

assimilation, colony morphology and pigment production on Hi-Chrom *Candida* agar (Hi-media Laboratories Pvt Ltd, India) (Deorukhkar S. C.2014.). Hi-*Candida* identification kit (Hi-media Laboratories Pvt. Ltd, India) was also used to identify *Candida* isolates. For this, test was done as per instruction of manufacturer.

Antifungal sensitivity of *Candida* isolates was done by Kirby-Bauer disc diffusion method. Mueller Hinton agar supplemented with 0.2% glucose and 0.5µg/ml methylene blue dye medium (MH-GMB) was used for this purpose (Clinical and Laboratory Standards Institute [CLSI]. 2004.).Azole group of Antifungal drug discs, such as; Fluconazole (25 µg), Ketoconazole (10 µg), Itraconazole (10 µg) were procured from Hi-media Laboratories Pvt Ltd India.

For preparation of inoculum, 24 h old culture grown on Sabouraud's dextrose agar (SDA) was used. For sensitivity test, 4-5 distinct colonies were suspended in 5 ml of sterile 0.85% saline and then; inoculum was spread on entire surface of MH-GMB with help of sterile cotton swab. Azole discs were placed on to the surface of media by using sterile forceps. Inoculated plates were incubated at 37oC for 24 h. Antifungal susceptibility testing were interpreted as per the approved Clinical and Laboratory Standard Institute guidelines (CLSI. 2004, CLSI,2002,Pfaller M. A.*et al.*, 2012).

Itraconazole and Fluconazole resistance was confirmed by quantitative determination of susceptibility of fungus to antifungal agent using MIC strip, obtained from Hi – media Pvt Ltd, India. The test was performed as per manufacturer's instruction.

C. albicans (ATCC 90028), *C. parapsilosis* (ATCC 22019), *C. tropicalis* (ATCC 750) and *C. krusei* (ATCC 6258) were used as

reference strains for quality control (Pfaller M. A. *et al.*, 2012).

Results and Discussion

From 1003 total clinical samples, we isolated 43 *Candida* spp among which, there were 20 *C. albicans* (46.5%), 11 *C. tropicalis* (24.5%), 10 *C. glabrata* (23.4%) and 2 *C. krusei* (4.6%) (Table 1). *C. krusei* showed 100% resistance to KT and FLC and 50% resistance to IT. *C. glabrata* showed only 10% resistance to KT and all *glabrata* spp were susceptible to FLC and IT. *C. albicans* isolates were 25% resistant to KT, 15% to FLC and 10% to IT where as, *C. tropicalis* showed 27.3% resistance to KT and FLC both and 15% resistance to IT.

In recent years, incidence of fungal infection has significantly increased. Several factors, such as; emergence of HIV/AIDS, widespread use of immunosuppressive drugs, indiscriminate use of broad spectrum antibiotics, introduction of many life saving medical devices, biofilm formation and invasive surgical interventions might be the underlying predisposing factors (Kobayashi CC *et al.*, 2004).

In our study, maximum number of *Candida* isolates was *C. albicans*, followed by *C. tropicalis*, *C. glabrata* and *C. krusei*. This finding is similar to the work done by some other researchers (Kobayashi CC *et al.*, 2004, lvarez-Lerma F.A. *et al.*, 2003, Gonzalez Gravina H, Gonzalez Gravina H *et al.*, 2007). Predisposing factors for emergence of NAC group as pathogen may be due to prematurity, use of broad-spectrum antibiotics, immunosuppression and empirical use of antimycotic drugs. Clinical manifestations of infections by different NAC spp may be same but resistance pattern to antifungal drugs are different because some of them are inherently resistant or acquire

resistance, or both, to antimycotic drugs (Sullivan D. J. *et al.*, 1996).

In our study, antifungal susceptibility of *Candida* isolates was done by disc diffusion technique. Disc diffusion method for yeast is similar to the routinely used Kirby-Bauer method done for antibiotic susceptibility testing (Rex J *et al.*, 2001). It is relatively cost effective and convenient method, which can be readily done in routine laboratories (Deorukhkar S C *et al.*, 2017).

We also detected MIC of Itraconazole and Fluconazole. Although qualitative results obtained by disk diffusion method are useful in routine laboratory diagnosis, quantitative MIC detection is sometimes required for treatment of invasive infection. Other researchers also observed that e-strip test is quite simple, rapid, cost effective and can be easily done in routine laboratory practice. They also reported that this method could produce similar results as in reference methods for yeast (Ana AI *et al.*, 2015).

Fluconazole resistance was significantly high among NAC spp like *C. krusei* (100%), *C. glabrata* (2%) and *C. tropicalis* (21%). *C. albicans* was 30.1% resistant to fluconazole. *C. tropicalis*, which initially considered as fluconazole sensitive; now a days has been reported as highly resistant as reported in various studies (M. A. Pfaller. 2007, Y-L Yang. 2004). Reason for this is not known yet and this can be a future research topic for investigators. Equally, significantly high incidence of resistance against other azole drugs was observed in this study. *C. glabrata* was found to be least resistant among all the *Candida* isolates (Table 1).

Azole group of antifungal agents is most commonly used Antifungal agent for the treatment of candidiasis. These drugs are safe with less side effects and act against all

clinical types of Candidiasis. Therefore, resistance to these drugs is a matter of concern (M. Me´an *et al.*, 2008). Mechanisms of such resistance can be due to modifications

of target enzymes, low access of the drug to the target, or a combination of both (S. Silva *et al.*, 2012).

Table.1 Distribution of different *Candida* isolates (n = 43)

Fungal isolates	Number (%)
<i>C.albicans</i>	20 (46.5%)
<i>C.tropicalis</i>	11(24.5%)
<i>C.glabrata</i>	10 (23.4%)
<i>C. krusei</i>	02 (4.6%)

Table 1 the highest number of isolate was *C. albicans*, followed by *C.tropicalis*, *C.glabrata* and *C. krusei*.

Table.2 Antifungal resistance pattern of *Candida* isolates n=43)

<i>Candida</i> isolates	KT(10 µg)No of resistant strain (%)	FLC (25 µg)No of resistant strain (%)	IT ((10 µg)No of resistant strain (%)
<i>C.albicans</i> n=20	5(25%)	3(15%)	2(10%)
<i>C. tropicalis</i> n= 11	3(27.3%)	3(27.3%)	2(15%)
<i>C.glabrata</i> n=10	1(10%)	00 (00)	00(00)
<i>C.krusei</i> n= 02	2(100%)	2(100%)	1(50%)

Table 2 Resistance patterns of *Candida* isolates to azole derivatives.*C. krusei* showed 100% resistance to KT and FLC and 50% resistance to IT. *C. glabrata* showed only 10% resistance to KT and all *glabrata* spp were susceptible to FLC and IT.

In conclusion, this study identified *Candida* spp. isolated from various clinical specimens and their susceptibility pattern to azole derivatives from this part of India. Increasing resistance pattern of *Candida* spp to azole derivatives was noted. Species identification and antifungal susceptibility testing of *Candida* spp. should be done regularly to help the treatment process of mycotic infection.

Conflict of Interests

There is no conflict of interests regarding the publication of this paper.

Acknowledgments

Authors are grateful to the management of Hind Institute of Medical Sciences, Barabanki, Uttar Pradesh, India, for their encouragement

and support throughout the study.

References

- Ana A-I, Marcia SCM, Rodriguez T.2015. Susceptibility test for fungi: clinical and laboratorial correlations, *Med Mycol*; 57 (suppl 19): 57 – 64.
- Clinical and Laboratory Standards Institute (CLSI),2002. *Reference Method For Broth Dilution Antifungal Susceptibility Testing of Yeasts*, Approved standard M27-A2, Clinical Laboratory Standard Institute, Wayne, Ind, USA, 2nd edition.
- Clinical and Laboratory Standards Institute (CLSI). 2004. *Reference Method For Antifungal Disk diffusion Susceptibility Testing of Yeasts*, Approved standard M44-A, Clinical Laboratory Standard

- Institute, Wayne, Ind, USA, 2nd edition.
- Deorukhkar S C, Roushani S. 2017. Fluconazole resistance in *Candida* Species: Ten Year's Experience at a Rural Tertiary Care Teaching Hospital in India. *J Infect Dis Pathol* 1: 102.
- Deorukhkar S. C. and Saini S. 2014. Laboratory approach for diagnosis of candidiasis through ages, *Int J Current Microbiol and Appl Sci*, 3, 1, 206– 218.
- Gonzalez Gravina H, Gonzalez de Moran E, Zambrano O, Lozano Chourio M, Roudriquez de Valero S, *et al.*, 2007. Oral candidiasis in children and adolescents with cancer. Identification of *Candida* spp. *Med Oral Pathol Oral Cir Bucal* 12: E419-23.
- Kauffman CA. 2005. Candiduria. *Clin Infect Dis*; 41(suppl 6): 5371 – 6.
- Kobayashi CC, de Fernandes OF, Miranda KC, de Sousa ED, Silva Mdo R. 2004. Candiduria in hospital patients: a study prospective. *Mycopathologia* 158: 49-52.
- Ivarez-Lerma F. A', Nolla-Salas J., León C. *et al.*, 2003. Candiduria in critically ill patients admitted to intensive care medical units. *Intensive Care Med*, 29, 7, 1069–1076.
- M. A. Pfaller and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. *Clin Microbiol Rev*, 20, 1, 133–163.
- M. Me'an, O. Marchetti, and T. Calandra. 2008. Bench-to bedside review: *Candida* infections in the intensive care unit. *Critical Care*, 12, 1, article 204.
- Pfaller M. A. and Diekema D. J. 2012. Progress in antifungal susceptibility testing of *Candida* spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012, *J Clin Microbiol*, 50, 9, 2846–2856.
- Rex JH, Pfaller M, Walsh T, Chaturvedi V, Espinel-Ingro A, *et al.*, 2001. Antifungal susceptibility testing: Practical aspects and current challenges. *Clin Microbiol Rev* 14: 643-58.
- S. Silva, M. Negri, M. Henriques, R. Oliveira, D. W. Williams, and J. Azeredo. 2012. *Candida glabrata*, *Candida parapsilosis* and *Candida tropicalis*: biology, epidemiology, pathogenicity and antifungal resistance. *FEMS Microbiol Rev*, 36, 288–305.
- Sardi J. C. O., Scorzoni L., Bernardi T., Fusco-Almeida A. M., and Mendes Giannini M. J. S. 2013. *Candida* species: current epidemiology, pathogenicity, bio film formation, natural antifungal products and new therapeutic options, *J Med Microbiol*, 62, 1, 10–24.
- Snydman D. R. 2003. Shifting patterns in the epidemiology of nosocomial *Candida* infections, *Chest*, 123, 5, 500S– 503S.
- Sullivan D. J., Henman M. C., Moran G. P. *et al.*, 1996. Molecular genetic approaches to identification, epidemiology and taxonomy of non-*albicans* *Candida* species, *J Med Microbiol*, 44, 6, 399–408.
- Y-L Yang, Ho, H. H Cheng, M. Ho, and H J Lo. 2004. Susceptibilities of *Candida* species to amphotericin B and fluconazole: the emergence of fluconazole resistance in *Candida tropicalis*. *Infection control and hospital epidemiology*, 25,1, 60-64

How to cite this article:

Seema Bose, Amita Arya and Anjali Agarwal. 2018. Identification and Antifungal Susceptibility of *Candida* Isolates from Clinical Samples in a Tertiary Care Teaching Hospital of Central Uttar Pradesh. *Int.J.Curr.Microbiol.App.Sci.* 7(08): xx-xx. doi:

<https://doi.org/10.20546/ijcmas.2018.708.xx>